Background: Surveillance for hepatocellular carcinoma (HCC) is recommended in patients with
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and has an increasing incidence in the United States(1). Its incidence is expected to continue increasing over the next 20 years due to the current epidemic of advanced fatty liver disease and hepatitis C virus (HCV) cases(1). The prognosis for patients with HCC largely depends on tumor stage at the time of diagnosis. Patients with early HCC, defined as one nodule less than 5 cm or three nodules each less than 3 cm in diameter, can achieve 5-year survival rates near 70% with surgical resection or liver transplantation (2, 3) . These survival rates are in contrast to an average survival of less than one year for patients with advanced HCC (4) . Surveillance using ultrasound with or without alpha fetoprotein (AFP) at 6-12 month intervals strives to detect HCC at an early stage when it is amenable to curative therapy (5) and is recommended in high-risk populations (6) . A recent meta-analysis of prospective cohort studies found that HCC surveillance using a combination of ultrasound and AFP was highly efficacious, with a pooled sensitivity of 69% to find HCC at an early stage (7) . However, its effectiveness in clinical practice may be impacted by several factors, including low utilization rates among at-risk patients (8, 9) .
When implemented in clinical practice, HCC surveillance is a complex process requiring multiple components: 1) providers identify appropriate at-risk patients, 2) providers refer patients for surveillance, 3) patients understand and accept the tests, 4) the healthcare system schedules the tests, and 5) patients comply with surveillance recommendations (10) . The benefits of surveillance tests can often be reduced due to patient-(e.g. socioeconomic status and insurance), physician-(e.g. knowledge of guidelines), and system-level factors (e.g. availability of surveillance tests) (11) . Given this potential discrepancy between an intervention's efficacy (the effect under carefully controlled conditions) and effectiveness (the effect when implemented in real-world settings), there has been increasing emphasis on comparative effectiveness research to improve delivery of care (9, 12) . Accordingly, the NIH recently included the evaluation of realworld outcomes of healthcare interventions in liver disease as a priority area for future research.
Although the most recent American Association for the Study of Liver Disease (AASLD) guidelines recommend using ultrasound alone for HCC surveillance, the optimal surveillance method (ultrasound, AFP, or combination) in clinical practice has not been determined (6, 13, 14) . A significant amount of data exists supporting the use of AFP in HCC surveillance (13) .
Furthermore, we hypothesized that the gap between efficacy and effectiveness might be smaller for AFP than ultrasound because of the ease of obtaining a blood test. Therefore, the aim of our study was to determine the effectiveness of a surveillance strategy with ultrasound and AFP to detect HCC at an early stage in a real-world clinical setting. Patients underwent evaluation every 6 months by physical examination, routine biochemical tests (including CBC, creatinine, albumin, AST, ALT, alkaline phosphatase, bilirubin and INR), ultrasound, and AFP. Although all enrolled patients were prospectively followed, patients were managed as deemed appropriate by their hepatologist and not a strict study protocol. Importantly, patients were not reminded by study personnel to have screening done. Thus, while the accepted standard was ultrasound and AFP every 6-12 months, this did not happen in every patient for various reasons as described in the introduction. Patients were categorized as receiving consistent surveillance (ultrasound with or without AFP done at least annually), inconsistent surveillance (ultrasound or AFP done at a frequency of greater than one year but less than 2 years), or no surveillance (no surveillance test for more than 2 years). If an AFP level was elevated or mass lesion was seen on ultrasound, the usual practice was to perform triple-phase CT or MRI to evaluate the presence of HCC as recommended by AASLD guidelines. For study purposes, patients were followed until the time of HCC diagnosis, liver transplantation, death, or until the study was terminated on July 31, 2010. HCC cases diagnosed within the first six months of enrollment (prevalent cases) were excluded. Patients lost to followup were censored at the time of their last clinic visit. The Social Security Death File and the State of Michigan Death Records were utilized to ascertain date of deaths for patients.
Methods

Patients
Follow-up and Detection of HCC
HCC was diagnosed using AASLD guidelines, and the Barcelona Clinic Liver Cancer (BCLC) system was used for tumor staging (6) . For tumors greater than 2 cm in size, the 
Statistical Analysis
The cumulative probability of HCC development was determined by competing riskanalysis, with transplantation and death being regarded as competing outcomes. Patients who were lost to follow-up were right censored. We assessed the performance characteristics of AFP and of ultrasound for the detection of HCC. For each test, sensitivity and specificity for each test were calculated on a per-patient basis. Patients with an AFP level greater than 20 ng/mL or mass lesion on ultrasound without subsequent HCC confirmed on triple phase CT or MRI were recorded as a "false positive" test. Patients who were alive at the end of follow-up without developing HCC or undergoing liver transplantation were followed for at least an additional six months to confirm the absence of HCC. Univariate regression analysis using Mann Whitney rank-sum and Chi square tests was performed to identify factors associated with ultrasound's and AFP's sensitivity and specificity for the detection of HCC. Data analysis was performed using Stata 10 (College Station, TX).
Results
Patient Characteristics
Between January 2004 and September 2006, 446 patients with cirrhosis were identified and prospectively followed. Four patients were discovered to have prevalent tumors within six months of enrollment and were excluded. Baseline characteristics of the remaining 442 patients are shown in 90% of the patients were Caucasian and 58.6% were men. The most common etiologies of cirrhosis were HCV (47.3%), cryptogenic (19.2%), and alcohol-induced liver disease (14.5%).
A total of 42.9% patients were Child Pugh class A and 52.5% were Child Pugh class B. Median Child Pugh and MELD scores at enrollment were 7 and 9 respectively. Median baseline AFP level was 5.9 ng/mL in patients who developed HCC, which was significantly higher than the median baseline AFP of 3.7 ng/mL in patients who did not develop HCC during follow-up (p<0.01).
Surveillance Utilization
The median follow-up of the cohort was 3.5 years (range 0.6-6.6). Follow-up was performed for at least one year in 392 (88.7%) patients, whereas 50 patients were followed for less than one year. Of the 442 patients in the final cohort, 69 (15.6%) were lost to follow-up prior to the study being terminated on July 31, 2010. During the 1454 patient-years of follow-up, 1555 AFP levels and 1238 ultrasounds were performed. Consistent surveillance was performed in 271 (61.3%) patients, whereas 107 (24.2%) patients received inconsistent surveillance, and 64 
Incidence of HCC
Over the 1454 person-year follow-up period, 41 patients developed HCC for an annual incidence of 2.8%. The cumulative 3-and 5-year probabilities of HCC development were 5.7% and 9.1%, respectively, based on the competing risk model (Figure 1 Table 2) .
Effectiveness of Ultrasound and AFP for HCC Surveillance
The method of HCC detection during surveillance is recorded in Table 2 . The per-patient sensitivity and specificity of ultrasound for the detection of HCC were 43.9% (18/41) and 91.5% (367/401) respectively (Table 3) The sensitivity of ultrasound for detecting HCC was significantly associated with race (p=0.04) and baseline MELD score (p=0.03). Whereas 18 (50%) of the 36 Caucasian patients with HCC had their tumors detected on surveillance ultrasound, all 5 non-Caucasian patients had their tumors missed by surveillance ultrasound. Patients with HCC detected on ultrasound also had higher median MELD scores than those whose tumor was missed by surveillance ultrasound (11.5 vs. 9.0). The sensitivity of ultrasound was 60% in patients with a MELD score greater than 10, compared to only 18.8% in those with lower MELD scores. We did not identify any factors associated with AFP's sensitivity for detecting HCC, although this could have been due to limited statistical power.
The specificity for both ultrasound and AFP were both significantly associated with underlying hepatitis C liver disease. Whereas HCV etiology was associated with a higher specificity for surveillance ultrasound (94.6% vs. 89.0%, p=0.04), it negatively impacted the specificity of AFP (83.7% vs. 97.2%, p<0.001). The specificity for AFP was also associated with Caucasian race, with a specificity of 92.6% in Caucasians, compared to only 70.8% in nonCaucasians (p<0.001). Our study is the first to evaluate the effectiveness of a surveillance program using ultrasound and AFP every 6-12 months among patients with cirrhosis in a real-world clinical setting. Ultrasound and AFP both had sensitivities near or below 65% for detecting HCC in a real-world setting, although this was increased to 90% when used in combination. The sensitivity of the tests in combination was significantly higher than that of ultrasound alone (p<0.001) and AFP alone (p=0.02), with a minimal loss in specificity. Had all patients undergone surveillance using ultrasound alone, this would have led to 13 (32%) diagnoses of HCC at early stage with 48 unnecessary CT or MRI scans due to false positive results, whereas combination surveillance detected 26 (63%) HCC at an early stage, with 90 unnecessary CT or MRI scans.
A recent meta-analysis of prospective cohort studies found that the pooled sensitivity of ultrasound to find early stage HCC was 63% when used alone and 69% when used in combination with AFP(7). In our cohort, the sensitivity of ultrasound for early stage tumors was only 32%, which was significantly increased to 63% (p=0.008) when used in combination with AFP. Only eight patients had a positive ultrasound and elevated AFP prior to HCC diagnosis, with the majority only having one positive surveillance study. These results highlight the large discrepancy between the effectiveness of surveillance ultrasound and its reported efficacy in previously published prospective studies. Thus, although AFP may be of minimal benefit in prospective clinical trials, it appears to provide a greater benefit among patients in real-world clinical settings. A recent cost-effective analysis found that combination ultrasound and AFP was the preferred strategy when ultrasound's sensitivity fell below 65% (15) . In contrast to current guideline recommendations (14) , these results suggest that AFP should continue to be used in combination with ultrasound during HCC surveillance. Several studies have suggested that the effectiveness of HCC surveillance may be impacted by low utilization rates among at-risk patients (8, 9, 16) . Consistent surveillance was performed in 60% of patients in our study, which is substantially higher than the 19% pooled surveillance rate from a recent meta-analysis(17). Despite these high surveillance utilization rates, 10 patients with HCC did not have an ultrasound within 6 months of diagnosis. Although underutilization was a factor in determining ultrasound's effectiveness, the sensitivity of ultrasound for HCC was still only 58% (18/31) when excluding the ten patients without an ultrasound within 6 months of HCC diagnosis. Surveillance using a combination of ultrasound and AFP still had a significantly higher sensitivity for HCC (p=0.002).
One reason for the apparent gap between efficacy and effectiveness of ultrasound may be related to operator quality. In clinical trials, ultrasounds are often performed by physicians or experienced ultrasonographers using standardized imaging protocols, but in real practice these exams are usually performed by radiology technicians with limited medical knowledge(18).
Additionally, patients often obtain their ultrasounds in local community centers instead of at a single centralized tertiary care center, introducing more variability in operator experience and technique. Alternatively, this difference in sensitivity could also be related to differences in patient characteristics, as is seen with breast density for mammography(19). For HCC surveillance, the ability of ultrasound to accurately visualize the liver in patients with morbid obesity or a very nodular liver may be impaired(20). Upon exploratory regression analysis, we found that the sensitivity of ultrasound was associated with Caucasian race and higher MELD scores. Although we did not find any association with obesity and Child Pugh score, this may 
impact of operator dependency and patient characteristics on the sensitivity of ultrasound to help improve its performance in detecting early stage HCC.
It is important to note that our study had several limitations. Our study was performed in a single tertiary care center and may not be generalized to other practice settings. Additionally, the performance characteristics of surveillance ultrasound likely vary by operator experience and center. Another limitation of our study is the fact that approximately 18% of the patients were lost to follow-up, although the median follow-up for these patients was 2.8 years and their survival status was verified through the social security death file. Furthermore, these patients had less advanced cirrhosis (lower Child Pugh class and MELD scores) and were less likely to develop hepatic decompensation, HCC, or death. Overall, we believe that the limitations of this study are outweighed by its notable strengths including its prospective enrollment, its large sample size, and its diverse population with both viral and non-viral liver disease. Most importantly, our study is one of the first to describe the real-world effectiveness of surveillance in a cohort of American patients with cirrhosis.
In conclusion, there is a large gap between the efficacy and effectiveness of ultrasound and AFP for HCC surveillance among patients with cirrhosis. Ultrasound and AFP are both suboptimal surveillance tools when used alone and should be used in combination to help maximize sensitivity for early stage HCC. Overall, an HCC surveillance program in patients with cirrhosis can be effective, detecting over 70% of all tumors at an early stage.
Grant Support
This project was supported, in part, by grants DK 064909, DK077707, and KL2 RR024983-05 
